Although some of the improvement is a result of prevention and screening, advances in technology and in chemotherapy and immunotherapy pharmaceuticals have been major driving forces in the decline in cancer-related death.
More From BioPortfolio on "Developing Alternative Payment Models That Providers and Commercial Payers Support"